A new three-layer tablet combining artesunate (AS) and amodiaquine (AQ), named TRIMALACT, was developed for treating uncomplicated falciparum malaria.
The study conducted in the Democratic Republic of Congo involved administering the combination to adults and monitoring parasitemia, fever, and blood levels of the drug metabolites using advanced chromatography techniques.
The results showed a 100% efficacy rate for the combination treatment, which was well tolerated, but also revealed high prevalence of resistance markers to common malaria treatments.